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OBJECTIVES This study investigated the effects of androgens on gene expression in male- and female-
donor macrophages.
BACKGROUND Men have more severe coronary disease than women. Androgen exposure increases foam cell
formation in male but not female macrophages, and male macrophages express4-fold more
androgen receptor messenger ribonucleic acid than female macrophages. Therefore, androgen
exposure may have gender-specific and potentially pro-atherogenic effects in macrophages.
METHODS Utilizing complementary deoxyribonucleic acid arrays, we studied the effects of a pure
androgen (dihydrotestosterone, 40 nmol/l) on human monocyte-derived macrophages from
healthy male and female donors (n  4 hybridizations; 2 men, 2 women). Differential
expression of atherosclerosis-related genes was confirmed by real-time reverse transcription-
polymerase chain reaction (RT-PCR) in five male and five female donors. Functional
corroboration of foam cell formation-related findings was undertaken by experiments using
125I-acetylated low-density lipoprotein (AcLDL).
RESULTS In male macrophages, androgen treatment produced differential up-regulation of 27 genes
concentrated in five functional classes: 1) lipoprotein processing; 2) cell-surface adhesion; 3)
extracellular signaling; 4) coagulation and fibrinolysis; and 5) transport protein genes. By
contrast, none of 588 genes were up-regulated in female macrophages. By RT-PCR, we
confirmed the gender-specific up-regulation of six of these atherosclerosis-related genes: acyl
coenzyme A:cholesterol acyl transferase I, lysosomal acid lipase (LAL), caveolin-2, CD40,
vascular endothelial growth factor-165 receptor, and tissue factor pathway inhibitor. Func-
tionally, androgen-treated male macrophages showed increased rates of lysosomal AcLDL
degradation, by 45% to 75% after 15 to 20 h of 125I-AcLDL incubation (p  0.001),
consistent with increased LAL activity.
CONCLUSIONS Androgens increase expression of atherosclerosis-related genes in male but not female
macrophages, with functional consequences. These findings may contribute to the male
predisposition to atherosclerosis. (J Am Coll Cardiol 2003;42:1306–13) © 2003 by the
American College of Cardiology Foundation
Men have earlier and more severe atherosclerosis than
women, independent of environmental risk factor exposure
(1). Indeed, the incidence of coronary deaths in men age 35
to 64 years exceeds that in age-matched women by up to
500% (2). To date, the causes of this gender difference
remain unclear. Such observations have produced consider-
able interest in the potential role of sex hormones in
atherogenesis. The apparent atheroprotective effect of es-
trogen has been studied extensively, and, contrary to expec-
tations, the first prospective randomized controlled trials to
test this hypothesis have shown adverse effects (3,4). The
role of androgens is now also being scrutinized.
Macrophages play a key role in both the early (via foam
cell formation) and late (via inflammatory and other medi-
ators) stages of atherosclerosis (5). Formation of the mac-
rophage foam cell is due to the uptake of modified lipopro-
teins by monocyte-derived macrophages (MDMs) in the
arterial wall (6). A growing body of evidence shows that sex
steroid hormones regulate processes integral to human
macrophage foam cell formation (7). Furthermore, sex
steroids may act in a gender-specific manner, with greater
effects of estrogens and/or androgens in male or female cells
(7). This gender-related regulation might have important
implications for understanding the basis of (and developing
treatments for) the gender gap in atherosclerosis.
We recently demonstrated that androgen exposure in-
creases foam cell formation in male- but not female-donor
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human MDMs, via an androgen receptor (AR)-mediated
pathway (8). Furthermore, male-donor MDMs express at
least four-fold more AR messenger ribonucleic acid (RNA)
than MDMs from female donors (8). As the AR mediates
the genomic effects of androgen action, androgens may have
gender-specific and potentially pro-atherogenic effects on
macrophage gene expression. Utilizing complementary de-
oxyribonucleic acid (cDNA) array analysis, we have system-
atically investigated the effects of androgen exposure on
gene expression in male- and female-donor human MDMs
in order to identify: 1) atherosclerosis-related genes poten-
tially regulated by androgen exposure; and 2) cellular mech-
anisms involved in the androgen regulation of macrophage
foam cell formation.
METHODS
Isolation, culture, and hormone treatment of human
monocytes. Monocytes were isolated from whole blood of
young healthy adult male and premenopausal female donors
(inclusion criteria: Caucasian, 35 years of age, without
pre-existing cardiovascular disease or cardiovascular risks,
and no hormone therapy) by counterflow centrifugation
elutriation (9) and cultured in phenol red-free RPMI (Life
Technologies, Carlsbad, California) containing 10% post-
menopausal human serum (17-estradiol 75 pmol/l, pro-
gesterone 0.8 nmol/l, and testosterone 2 nmol/l), pen-
icillin G (50 U/ml), and streptomycin (50 g/ml). Over a
nine-day maturation period, the following treatments were
added with each media change from days 3 to 9: 1)
dihydrotestosterone (DHT) at 40 nmol/l, or 2) vehicle
control (0.1% ethanol). Monocyte purity was 95% and
viability 95% (trypan blue) in all experiments.
RNA isolation and cDNA array experiments. To identify
atherosclerosis-related genes potentially regulated by andro-
gen exposure, cDNA arrays were used (ATLAS Human
Cardiovascular Array containing 588 genes and 9 house-
keeping genes, Clontech Laboratories, Palo Alto, Califor-
nia). Total RNA was isolated from both control- and
androgen-treated macrophages at maturation (day 9). Four
separate array analyses of gene expression in control- versus
androgen-treated MDMs from four consecutive donors
(two men and two women) were undertaken. Probe synthe-
sis, array hybridization, and phosphorimager analysis were
performed using a modification of published methods (10).
Briefly, cDNA probes both control- and androgen-treated
MDMs, synthesized by reverse transcription of 5 g total
RNA in the presence of 32P-dATP, were hybridized for
16 h onto separate but identical array membranes, and the
signal intensities were measured by phosphorimager analysis
(Fujix Bas 1500 Phosphorimager, Fuji, Tokyo, Japan).
Pairwise comparative gene expression between controls and
androgen-treated MDMs from each donor was undertaken
after signal intensities were converted to a ratio adjusted for
background and housekeeping gene (60S rRNA) expres-
sion. Data for each gene were used only when the signals for
that gene from both membranes were at least 50% above
background. Hence, our experiments preferentially detected
up-regulation rather than down-regulation.
The cDNA array reproducibility was evaluated by under-
taking two consecutive array hybridizations using the same
two samples of control- and androgen-treated RNA. These
data demonstrated that 97% of differential expression values
in each experiment were within two-fold of each other.
DIFFERENTIAL EXPRESSION CRITERIA. Individual genes
that exhibited at least two-fold up-regulation in the
androgen-treated cells relative to control in both mem-
branes for each gender were defined as being differentially
expressed.
SELECTION OF HOUSEKEEPER GENE. A non-linear power
regression analysis of cDNA array signal intensities from
both control- and androgen-treated arrays of each subject
was used to identify the housekeeper gene. On all regression
plots, 60S rRNA did not exhibit differential expression with
androgen treatment and was selected as the housekeeper
gene.
Relative real time reverse transcription-polymerase chain
reaction (RT-PCR). Confirmation of array findings in six
atherosclerosis-related genes was undertaken in MDMs
from five male and five female donors by relative real-time
RT-PCR with SYBR Green I (Molecular Probes, Eugene,
Oregon) monitoring using a modification of published
methods (11). The MDMs for these experiments were
cultured using the same protocols and treated in the same
hormonal conditions as for the cDNA array studies. The
genes assayed included: acyl coenzyme A:cholesterol acyl-
transferase I (ACAT); lysosomal acid lipase (LAL); caveo-
lin-2; CD40; vascular endothelial growth factor (VEGF)-
165 receptor; and tissue factor pathway inhibitor (TFPI).
Reverse transcription of each RNA sample was performed
in duplicate according to standard protocols. Relative real-
time PCR reactions were performed in duplicate for each
cDNA sample for each gene of interest (Applied Biosystems
Incorporated [ABI] Model 7700 Sequence Detector, PE
Biosystems, Foster City, California) and analyzed using
ABI Prism Sequence Detector Software version 1.6.3 (PE
Abbreviations and Acronyms
ACAT  acyl coenzyme A:cholesterol acyl transferase I
AcLDL  acetylated low-density lipoprotein
AR  androgen receptor
cDNA  complementary deoxyribonucleic acid
DHT  dihydrotestosterone
LAL  lysosomal acid lipase
MDM  monocyte-derived macrophage
RNA  ribonucleic acid
RT-PCR  reverse transcription-polymerase chain
reaction
TFPI  tissue factor pathway inhibitor
VEGF  vascular endothelial growth factor
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Biosystems). The housekeeping gene, 60S rRNA, was also
measured for normalization of real-time PCR results.
The primer sequences were: ACAT forward 5 AGT-
TGACAGCAGAGGCAGAG 3, reverse 5 GGATA-
AAGAGAATGAGGAGGG 3; LAL forward 5
GCAACAGCAGAGGAAATAC 3 , reverse 5
GAGAATGACCCACATAATACAC 3; caveolin-2
forward 5 TGCAGACAATATGGAAGAG 3, reverse
5 GAAATGAACAGAACAGTGG 3; CD40 forward
5 GCACCTCAGAAACAGACAC 3, reverse 5
GGACCACAGACAACATCAG 3; VEGF-165 recep-
tor forward 5 CTCATCACCATCATAGCC 3, reverse
5 CAACTTCACACCATCCAC 3; TFPI forward 5
GTGAATAACTCCCTGACTCC 3, reverse 5 TT-
TCACTCTCTGCTTCTTTC 3; and 60S rRNA for-
ward 5 GGAGAAGAGGAAAGAGAAAG 3, reverse
5 CAACGCATGAGGAATTAAC 3.
Functional studies on lipoprotein metabolism. Lipopro-
tein uptake and lysosomal degradation studies were con-
ducted in both control- and androgen-treated (DHT 400
nmol/l) male-donor MDMs after incubation with 125I-
acetylated low-density lipoprotein (AcLDL). Cell-surface–
bound AcLDL was determined after a 4-h incubation at
4°C with 125I-AcLDL with and without a 30-fold excess of
unlabeled AcLDL. Specific binding was calculated by sub-
tracting the results in the presence of unlabeled AcLDL
from that in its absence (12). Binding parameters were
analyzed using the LIGAND computer program (BIO-
SOFT, Cambridge, United Kingdom). Lysosomal degrada-
tion of AcLDL was determined as trichloroacetic acid-
soluble, non-iodide 125I in the post-incubation medium (12)
following incubation at 37°C with 20 g/ml 125I-AcLDL
(with or without a 30-fold excess of unlabeled Ac LDL) for
6, 16, and 20 h. Retroendocytosis studies were conducted to
using a modification of published methods (13). Briefly,
MDMs were incubated with 20 g/ml 125I-AcLDL at
37°C for up to 120 min. Following incubation, cells were
cooled to 4°C and washed five times with phosphate
buffered saline containing 2 mg/ml bovine serum albumin,
once with an acid wash (0.2 mol/l acetic acid, 0.5 mol/l
sodium chloride, pH 2.4), followed by three times with
phosphate buffered saline. Retroendocytosis of AcLDL was
determined by measuring release of trichloroacetic acid-
precipitable 125I-material during a 1-h chase period at 37°C
(13).
Statistical analysis. All results are expressed as mean 
SEM. Statistical comparisons were performed using paired
or unpaired t tests, as appropriate. In the RT-PCR exper-
iments, a repeated measures design was adopted in that both
control- and DHT-treated macrophages are derived from
the same subject. For these experiments, gene expression in
control- versus DHT-treated cells in each gender were
compared one gene at a time using a paired t test. Where
multiple comparisons were performed—for example, when
comparing gene expression by real-time RT-PCR, p values
were adjusted according to Hochberg’s modification of the
Bonferroni procedure (14). Statistical analysis was per-
formed using GraphPad Prism version 3.0a (GraphPad
Software, San Diego, California), and regression plots were
generated using Kaleidagraph 3.0 (Synergy Software, Read-
ing, Pennsylvania).
RESULTS
Effects of androgen exposure on male and female donor
macrophage gene expression: cDNA array findings. In
cDNA array analyses of MDMs from two consecutive
subjects for each gender, androgen exposure in male-donor
MDMs up-regulated the expression of 27 genes. The genes
encoded for proteins that were categorizable into five
functional clusters: 1) lipoprotein and other metabolic
pathways; 2) adhesion, inflammation, and cell-surface anti-
gens; 3) coagulation and fibrinolysis; 4) extracellular
signaling/receptor-associated proteins; and 5) transport pro-
teins (Table 1, Figs. 1A and 1B). By contrast, in female-
donor MDMs, no gene met our criteria of being up-
regulated at least two-fold in two consecutive individuals by
cDNA array analysis.
Real time relative RT-PCR. The androgen-dependent,
gender-specific up-regulation of six atherosclerosis-related
genes was confirmed by real time RT-PCR, by comparing
the expression of each gene in androgen- versus control-
treated MDMs from five consecutive male and five consec-
utive female donors. Gene expression for each subject was
quantified four times—twice on each of two separate cDNA
syntheses). In male-donor MDMs, androgen exposure up-
regulated the expression of ACAT by 5-fold, LAL by
3.8-fold, caveolin-2 by 3.4-fold, CD40 by 5.5-fold, VEGF-
165 receptor-1 by 3.7-fold, and TFPI by 4.8-fold, respec-
tively (p  0.005 vs. control for all genes). By comparison,
androgen exposure had no significant effect on the expres-
sion of the same genes in female donor MDMs when
compared with control (p  0.1 vs. control for all genes)
(Fig. 1C).
Functional studies: the effect of androgen exposure and
macrophage lipoprotein metabolism. Because DHT in-
creases cholesteryl ester accumulation in male-donor
MDMs (8), we used the cDNA array findings to identify
cellular mechanisms for androgen action. Functional anal-
ysis of cDNA array findings indicated that androgen effects
on foam-cell-formation–related processes involved up-
regulation of genes involved in lysosomal degradation
(LAL) and post-lysosomal processing (ACAT and hor-
mone sensitive lipase). In contrast, the expression of genes
involved in pre-lysosomal processes, such as modified low-
density lipoprotein binding and uptake (macrophage scav-
enger receptor types A1 and A2), were unaffected by
androgen exposure. Therefore, in vitro experiments were
undertaken to evaluate the effects of androgen exposure on
the uptake and lysosomal processing of modified low-
density lipoprotein by male-donor MDMs and to corrobo-
rate the functional implications of our array findings.
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LYSOSOMAL DEGRADATION OF MODIFIED LOW-DENSITY
LIPOPROTEIN. To evaluate the functional significance of
increased LAL expression, we studied the effects of andro-
gen exposure on lysosomal lipoprotein degradation in male-
donor macrophages by incubation of macrophages with
radiolabelled AcLDL. Androgen-treated male donor mac-
rophages showed increased rates of lysosomal degradation of
AcLDL at 37°C compared with controls (Fig. 2A). This
difference was highly significant by 20 h of incubation with
radiolabelled AcLDL (p  0.001).
SCAVENGER RECEPTOR BINDING AND RETROENDOCYTOSIS
STUDIES. No difference existed between control- and
DHT-treated male MDMs in specific or non-specific
cell-surface binding of AcLDL with increasing concentra-
tions of radiolabelled ligand (Fig. 2B). This was confirmed
by computational analysis of binding parameters (LIGAND
program, BIOSOFT), which showed no difference in bind-
ing affinity (Kd 1.77 108 mol/l and Kd 1.91 108 mol/l
in controls and DHT-treated cells, respectively; p  0.9) or
receptor site concentrations (1.23  1010 mol/l and 1.35
 1010 mol/l in controls and DHT-treated cells, respec-
tively; p  0.3) between androgen and control treatments.
In addition, there was no difference in retroendocytosis of
undegraded AcLDL between control- and DHT-treated
cells during pulse-chase experiments where the only source
of labeled lipoprotein was from an intracellular site of
previously endocytosed I125-AcLDL (100 5 % and 103
4% for control- and DHT-treated cells, respectively; p 
0.1).
In the absence of androgen effects on scavenger receptor
binding and retroendocytosis, the effect of DHT on lyso-
somal lipoprotein degradation is consistent with a primary
effect on increasing the activity of LAL. Overall, these
functional data are consistent with the gene expression
findings noted above.
DISCUSSION
Male gender is a strong risk factor for atherosclerosis,
independent of environmental risk factor exposure (1).
Therefore, gender differences in sex hormones and genetics
may contribute to the male predisposition to atherosclerosis.
To date, few studies have investigated gender-dependent
differences in the regulation of atherosclerosis-related genes.
Using cDNA array analysis, we report that androgens
regulate the macrophage expression of a large number of
atherosclerosis-related genes in a strikingly gender-
dependent manner. In male-donor human MDMs, andro-
gen exposure up-regulated the expression of 27 genes with
a range of atherosclerosis-related functions, including li-
poprotein metabolism, adhesion, inflammation, coagula-
Table 1. Genes Up-Regulated by Androgen Exposure in Male- and Female-Donor Human Macrophages*
Gender Gene Functional Class Accession No. Gene Name
Male Lipoprotein and other metabolic pathways L21934 Acyl coenzyme A:cholesterol acyltransferase
U40002 Hormone-sensitive lipase
M74775 Lysosomal acid lipase
AF035752 Caveolin-2




M36693 Superoxide dismutase 2
Adhesion, inflammation, and cell surface antigens X60592 CD40
AF047826 Cadherin 19, type 2
U41070 Leukotriene B4 receptor
X05908 Annexin I
U34802 Gap junction protein alpha-8
U49240 Symplekin
Coagulation and fibrinolysis D00017 Annexin II
J03225 Tissue factor pathway inhibitor
D29992 Tissue factor pathway inhibitor 2
V00595 Prothrombin precursor
Extracellular signaling/receptor-associated genes L25615 Arginine vasopressin receptor 1A
X15357 Atrial natriuretic peptide receptor A
L13436 Atrial natriuretic peptide receptor B
AF016050 Vascular endothelial cell growth factor 165 receptor
AF016098 Vascular endothelial cell growth factor 165 receptor 2
Transport proteins Y10255 Fatty acid binding protein 3
M94856 Fatty acid binding protein 5
M20747 Insulin-responsive glucose transporter type 4
Female Nil Nil Nil
*Differential up-regulation was defined as an at least two-fold up-regulation in androgen-treated cells versus control in both arrays for each gender.
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Figure 1. Effects of androgen exposure on macrophage gene expression. (A, B) Gene expression profiles in control- and androgen-treated male
macrophages, respectively. There is enhanced expression of a large number of atherosclerosis-related genes (see Table 1). For example, the boxed areas
containing lysosomal acid lipase (LAL) and acyl coA:cholesterol acyl transferase (ACAT) are enlarged and shown on the right. (C) Differential gene
expression examined by reverse transcription-polymerase chain reaction (RT-PCR) shows the androgen-dependent gender-specific up-regulation of six
atherosclerosis-associated genes: 1) ACAT; 2) LAL; 3) caveolin-2; 4) CD40; 5) tissue factor pathway inhibitor; and 6) vascular endothelial growth factor
(VEGF)-165 receptor. In all genes studied by RT-PCR, androgen exposure produced up-regulation in gene expression in male-donor but not female-donor
macrophages (p  0.005 vs. control for all genes in male-donor cells as compared with p  0.1 vs. control for all genes in female-donor cells). Open bars
 controls; striped bars  40 nmol/l dihydrotestosterone.
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tion, and angiogenesis (Table 1). By contrast, no genes were
affected in female-donor MDMs. These array findings were
confirmed by real-time RT-PCR findings, as well as by the
demonstration of functional effects of androgen exposure on
macrophage lipoprotein metabolism.
We previously reported that androgen exposure increases
human macrophage foam cell formation in male-donor but
not in female-donor MDMs (8). The present study extends
these findings by demonstrating that androgens exert com-
plex and gender-specific effects on the expression of lipopro-
tein metabolism genes in male-donor MDMs. This involves
the up-regulation of genes involved in: 1) lysosomal lipopro-
tein processing (LAL), and 2) post-lysosomal processes
including intracytoplasmic cholesterol esterification (ACAT)
and cholesteryl ester hydrolysis (hormone-sensitive lipase). By
contrast, the expression of genes involved in modified low-
density lipoprotein binding and uptake (scavenger receptors
class A1 and A2) were unaffected by androgen exposure. As
androgens exert both genomic and non-genomic effects and
as changes in gene expression do not always reflect func-
tional changes, we undertook a series of lipoprotein metab-
olism studies to examine androgen regulation of modified
low-density lipoprotein cell surface binding, retroendocyto-
sis, and lysosomal degradation of lipoproteins. Our gene
expression findings are corroborated by in vitro functional
studies demonstrating that androgen exposure increases the
rate of lysosomal hydrolysis of lipoproteins in male-donor
MDMs, in the absence of androgen effects on scavenger
receptor binding, or retroendocytosis. These findings are in
keeping with an androgen-dependent up-regulation of LAL
activity in male-donor MDMs. The LAL plays a major role
in the delivery of atherogenic lipoproteins to the cell, by
hydrolyzing the cholesteryl ester moiety from lipoproteins
delivered to the lysosome via endocytosis or phagocytosis
into free cholesterol, thereby making free cholesterol avail-
able for intracytoplasmic re-esterification by ACAT (15).
Increase in LAL activity has thus been implicated in
promoting macrophage foam cell formation (15,16). Our
current findings also support a previous observation of
positive correlation between serum testosterone levels dur-
ing development and hormone-sensitive lipase protein levels
and enzymatic activity in the guinea pig testis (17). In male
MDMs, therefore, androgen exposure exerts widespread
effects on the expression of genes involved in lipoprotein
metabolism, with a net functional effect of increasing the
accumulation of cholesteryl esters.
The adherence of monocytes to vascular endothelium and
their subsequent transmigration into the vessel wall are key
early events in atherogenesis (5). We have previously re-
ported that androgen treatment of endothelial cells increases
human monocyte adhesion to endothelium in male-donor
cells via up-regulation of endothelial cell expression of
vascular cell adhesion molecule-1 (18). The present study
extends these observations from endothelial cells to mono-
cytes. In the current study, we found that androgen exposure
in macrophages produced a gender-specific up-regulation of
genes implicated in promoting the adherence of monocytes
to vascular endothelium (including CD40, leukotriene B4
receptor, and cadherin 19). CD40 ligation in human mac-
rophages has been shown to trigger the expression of
adhesion molecules including lymphocyte function-
associated antigen-1 and intercellular adhesion molecule-1
(19). Leukotriene B4, a potent chemoattractant and pro-
Figure 2. Effects of androgen exposure on macrophage lipoprotein metab-
olism. (A) Androgen exposure increased the rate of lysosomal degradation
of acetylated low-density lipoprotein (AcLDL) by male-donor monocyte-
derived macrophages—a finding consistent with increased lysosomal acid
lipase activity (p  0.001 for dihydrotestosterone [DHT]-treated vs.
control cells, at 20 h). (B) Androgen exposure had no effect on cell surface
binding of 125I-AcLDL (p  0.1 for androgen vs. control macrophages).
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inflammatory mediator, has also been implicated in mono-
cyte recruitment, activation, and adhesion. Leukotriene B4
receptor antagonism has been shown to reduce monocyte
infiltration and lipid accumulation in apoE-deficient mice
(20).
A number of the array findings from this study are also
consistent with available observational data. In clinical
studies evaluating the effect of androgens on coagulation,
exogenous testosterone has been reported to increase plasma
levels of prothrombin fragment F1.2 in healthy men (21),
but not in women with severe premenstrual syndrome (22),
which is consistent with a gender-dependent effect. In
animal models, androgen exposure up-regulates arginine
vasopressin receptor 1A messenger RNA in the male Syrian
hamster brain (23) and increases fatty acid binding protein
content in rat heart and skeletal muscle (24). Increasing
evidence shows the role of androgens in the control of
angiogenesis. Dihydrotestosterone up-regulates the expres-
sion of VEGF messenger RNA and VEGF biological
activity in an adult rat prostate (25), and testosterone
increases VEGF expression via an AR-dependent manner,
in an immortalized cell line S115 (26).
We and others have previously shown that male human
macrophages express higher levels of AR message than
female-donor cells (8,27). Moreover, in rat aortic smooth
muscle cells, AR protein levels are higher in male than in
female animals (28). Therefore, the marked gender speci-
ficity of androgen effects on macrophage gene expression is
most likely related to gender differences in MDM AR
content. Hence, gender differences in AR content may be a
key mediator of gender differences in vascular biology. This
hypothesis is supported by a recent study using male
testicular feminized rats, which express a non-functional
AR. In rats, the contractile response of the thoracic aorta to
vasopressin is three-fold higher in females than in males
(29). Stallone et al. (29) found that this gender difference in
vascular reactivity in rat aortas was abolished in AR-
deficient male testicular feminized rats, where responses to
vasopressin were similar to normal female rather than male
animals.
Regarding limitations, we used arrays with 588 cDNAs
with a high concentration of genes with established rele-
vance to atherosclerosis and vascular biology. A larger,
genome-wide screen might identify more androgen-
regulated genes within macrophages.
Dihydrotestosterone, a potent physiologic androgen spe-
cific for AR, was used at a concentration of 40 nmol/l on the
basis of previous foam cell and cell adhesion experiments
(8,18). As DHT is not aromatizable to estrogenic metabo-
lites, unlike testosterone (30), its use avoids the potentially
confounding effects of estrogens, as they have also been
shown to influence both gene expression and macrophage
lipid loading (31). Whereas DHT at 40 nmol/l is higher
than normal circulating levels (being ten-fold above the
normal serum concentration for male adults), this concen-
tration is physiologically relevant in our experiments as: 1)
testosterone, the major circulating androgen (usual serum
concentrations 20 to 32 nmol/l in men), is absent from our
culture milieu; and 2) plasma levels of DHT do not reflect
tissue formation (32), particularly in tissues possessing
5-reductase activity, such as macrophages (33,34). The
5-reductase enzyme converts testosterone to DHT, ac-
counting for 75% of tissue DHT, which is the final
androgenic messenger in many target tissues. This enzyme
is also present in the other major cell types in the athero-
sclerotic lesion: the endothelial cell (35) and the vascular
smooth muscle cell (36). Therefore, in the absence of
testosterone, the use of 40 nmol/l DHT for in vitro
treatment of MDMs is likely to be physiologically relevant
because DHT concentrations in tissues possessing 5-
reductase activity can approach concentrations in the order
of 100 nmol/l (34,37). Moreover, the functional effects of
gender-dependent, AR-mediated up-regulation of genes are
evident at DHT concentrations as low as 4 nmol/l (8). In
our previous dose-ranging studies, DHT produced a dose-
dependent, AR-dependent increase in male-donor MDM
cholesteryl ester accumulation which was demonstrable
between 4 to 400 nmol/l (inclusive), but had no effect on
cholesteryl ester accumulation in female-donor MDMs
even at concentrations as high as 400 nmol/l (8).
In summary, using differential gene-expression techniques,
we report for the first time that androgens regulate the
macrophage expression of a large number of atherosclerosis-
related genes in a highly gender-dependent manner. An-
drogen exposure up-regulated the expression of 27 genes,
many with known atherosclerosis-related functions, in
male-donor MDMs but had no significant effect on gene
expression in female-donor MDMs. These findings provide
novel insights into the effects of androgens on gene expres-
sion in the macrophage and suggest that androgens may be
involved in the complex and gender-dependent regulation
of a range of atherosclerosis-related processes including
foam cell formation, adhesion, inflammation, coagulation,
and angiogenesis. These gene expression findings are cor-
roborated by functional data confirming the androgen-
dependent up-regulation of lysosomal degradation of mod-
ified lipoproteins in male-donor MDMs—a process integral
to the delivery of atherogenic lipoproteins to the macro-
phage. These effects may contribute to the male predispo-
sition to atherosclerosis.
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